DHA STTR PHASE II PROPOSAL H2-0803, TITLED "DEVELOPMENT OF ANTIBODY TREATMENT OF MDR ESKAPE PATHOGEN, P. AE…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- HT942525C0011
- Contractor
- Awarding agency
- Department of Defense
- Sub-agency / office
- Defense Health Agency
- Award amount
- $1,299,972
- Period of performance
- Mar 12, 2025 – Jul 11, 2027
- NAICS
- 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- PSC AN12
- Place of performance
- TX
Public award description
DHA STTR PHASE II PROPOSAL H2-0803, TITLED "DEVELOPMENT OF ANTIBODY TREATMENT OF MDR ESKAPE PATHOGEN, P. AERUGINOSA.", MEDICAL R&D CONTRACT.
Find out who's winning similar federal contracts
Discover comparable awards, related contractors, and agency purchasing history.